Primary and secondary stroke prevention in nonrheumatic atrial fibrillation by oral anticoagulation

European Neurology

Volumn 50, Issue 3, 2003, Pages 127-135

  Stöllberger, Claudia ^a,b   Finsterer, Josef ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b NONE   (Austria)

Author keywords

Atrial fibrillation; Oral anticoagulation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANABOLIC AGENT; ANTICOAGULANT AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CIMETIDINE; CLOFIBRATE; COLESTYRAMINE; CORTICOSTEROID; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCONAZOLE; GRISEOFULVIN; HEPARIN; ISONIAZID; LEVOTHYROXINE; METRONIDAZOLE; MICONAZOLE; NAFCILLIN; OMEPRAZOLE; PHENYLBUTAZONE; PIROXICAM; PROPAFENONE; PROPRANOLOL; RIFAMPICIN; SUCRALFATE; SULFINPYRAZONE; UNINDEXED DRUG;

BLEEDING; CLINICAL TRIAL; DIABETES MELLITUS; DIETARY INTAKE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INHIBITION; DRUG POTENTIATION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGE FACTORS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DIABETES COMPLICATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EMBOLISM; HEART FAILURE, CONGESTIVE; HEMORRHAGE; HUMANS; HYPERTENSION; PRIMARY PREVENTION; RISK FACTORS;

EID: 18844479232     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073052     Document Type: Review

References (86)

1. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB: Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978;28:973-977.
2. Atrial Fibrillation Investigators, Atrial Fibrillation, Aspirin, Anticoagulation Study, Boston Area Anticoagulation Trial for Atrial Fibrillation Study, Canadian Atrial Fibrillation Anticoagulation Study, Stroke Prevention in Atrial Fibrillation Study, Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
3. Stöllberger C, Chnupa P, Kronik G, Brainin M, Finsterer J, Schneider B, Slany J: Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med 1998;128:630-638.
4. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
5. Bungart TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT: Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-46.
6. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K: Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1,010 treatment years in 551 outpatients. J Intern Med 1991;229:351-355.
7. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E: Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153:1557-1562.
8. Hart RG, Boop BS, Anderson DC: Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995;26:1471-1477.
9. The Stroke Prevention in Atrial Fibrillation Investigators: Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-416.
10. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S, on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy: Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423-428.
11. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E: Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76:12-16.
12. Steffensen FH, Kristensen K, Ejlersen E, Dahlerup JF, Sørensen HT: Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997;242:497-503.
13. Beyth RJ, Quinn LM, Landefeld CS: Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-99.
14. Pengo V, Legnani C, Noventa F, Palareti G: Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. ISCOAT Study Group. Italian study on complications of oral anticoagulant therapy. Thromb Haemost 2001;85:418-422.
15. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG: Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995;155:469-473.
16. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988.
17. Hart RG, Halperin JL: Atrial fibrillation and stroke. Concepts and controversies. Stroke 2001;32:803-808.
18. Bath PMW, Prasad A, Brown MM, MacGregor GA: Survey of use of anticoagulation in patients with atrial fibrillation. BMJ 1993;307:1045.
19. Albers GW, Yim JM, Belew KM, Bittar N, Hattemer CR, Phillips BG, Kemp S, Hall EA, Morton DJ, Vlasses PH: Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996;156:2311-2316.
20. Munschauer FE, Priore RL, Hens M, Castilone A: Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke 1997;28:72-76.
21. Albers GW, Bittar N, Young L, Hattemer CR, Gandhi AJ, Kemp SM, Hall EA, Morton DJ, Yim J, Vlasses PH: Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology 1997;48:1598-1604.
22. Lip GYH, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI: A survey of atrial fibrillation in general practice: The West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997;47:285-289.
23. Brass LM, Krumholz HM, Scinto JM, Radford M: Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-2389.
24. Stafford RS, Singer DE: Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998;97:1231-1233.
25. Perez I, Melbourn A, Kalra L: Use of antithrombotic measures for stroke prevention in atrial fibrillation. Heart 1999;82:570-574.
26. White RH, McBurnie MA, Manolio T, Furberg CD, Gardin JM, Kittner SJ, Bovill E, Knepper L: Oral anticoagulation in patients with atrial fibrillation: Adherence with guidelines in an elderly cohort. Am J Med 1999;106:165-171.
27. The Clinical Quality Improvement Network (CQIN) Investigators: Thromboembolic prophylaxis in 3,575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998;14:695-702.
28. Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage B: Underutilization of anti-thrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J 1999;137:307-312.
29. Wensley S, Keir S, Caine S, MacMahon M: Additional risk factors in atrial fibrillation patients not receiving warfarin. Age Ageing 1999;28:355-357.
30. Stöllberger C, Finsterer J, Slany J, für die COR-Survey Erhebung: Antithrombotische Therapie bei Vorhofflimmern und zusätzlichen Schlaganfall-/Embolie-Risikofaktoren. Z Kardiol 1999;88:442-447.
31. Adhiyaman V, Kamalakannan D, Oke A, Shah IU, White AD: Underutilization of antithrombotic therapy in atrial fibrillation. J R Soc Med 2000;93:138-140.
32. Carlsson J, Miketic S, Flicker E, Erdogan A, Haun S, Cuneo A, Tebbe U: Neurological events in patients with atrial fibrillation: Outcome and preventive practices. Z Kardiol 2000;89:1090-1097.
33. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators: Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. JAMA 1998;279:1273-1277.
34. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579S-589S.
35. Go AS, Hylek EM, Phillips KA, Borowsky LH, Henault LE, Chang Y, Selby JV, Singer DE: Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation 2000;102:11-13.
36. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B: Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis. JAMA 2002;288:2441-2448.
37. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III Randomised Clinical Trial. Lancet 1996;348:633-638.
38. Wehinger C, Stöllberger C, Länger T, Schneider B, Finsterer J: Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 2001;32:2246-2252.
39. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994;25:1157-1164.
40. Davis TME, Millns H, Stratton IM, Holman RR, Turner RC, for the UK Prospective Diabetes Study Group: Risk factors for stroke in type 2 diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 1999;159:1097-1103.
41. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebo-controlled randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillat. Lancet 19898631:175-179.
42. Petersen P, Kastrup J, Helweg-Larsen S, Boysen G, Godtfredsen J: Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Arch Intern Med 1990;150:819-821.
43. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, for the CAFA Study Coinvestigators: Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-355.
44. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
45. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW: Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Analysis of 2,012 participants in the SPAF I-III clinical trials. Stroke 1999;30:1223-1229.
46. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D, for the Veterans Affairs Stroke Prevention in Non-rheumatic Atrial Fibrillation Investigators: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412.
47. Hylek, EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
48. The Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation. 1. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
49. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
50. Berge E, Abdelnoor M, Nakstad PH, Sandset PM: Low-molecular weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: A double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000;355:1205-1210.
51. Saxena R, Lewis S, Berge E, Sandercock PAG, Koudstaal PJ, for the International Stroke Trial Collaborative Group: Risk of early death and recurrent stroke and effect of heparin in 3,169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001;32:2333-2337.
52. Lalouschek W, Lang W, Müllner M, on behalf of the Vienna Stroke Study Group: Current strategies of secondary prevention after a cerebrovascular event. The Vienna Stroke Registry. Stroke 2001;32:2860-2866.
53. Atrial Fibrillation Investigators: Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1,066 patients from 3 clinical trials. Arch Intern Med 1998;158:1316-1320.
54. BarSela S, Ehrenfeld M, Eliakim M: Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 1981;141:1191-1192.
55. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography: Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998;128:639-647.
56. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso-Garia A, Blomstrom-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation). Developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-2150.
57. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH, for the Warfarin Optimized Outpatient Follow-up Study Group: Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 1993;118:511-520.
58. The European Atrial Fibrillation Trial Study Group: Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.
59. Vázquez Ruiz de Castroviejo E, del Monte Trujillo Pérez M, Lozano Cabezas C, Avellaneda Molina C, Guzmaán Herrera M, Martínez Galiano E, Pousibet Sanfeliú H, Tarabini Castellani A, Pagola Vilardebó C, Alcalá Muñoz A: Complicaciones hemorragicas del tratamiento anticoagulante Analisis de factores predictores de riesgo. Sangre (Barc) 1999;44:216-221.
60. Casais P, Sánchez Luceros A, Meschengieser S, Fondevila C, Santarelli MT, Lazzari MA: Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000;63:192-196.
61. Hart RG, Halperin JL: Atrial fibrillation and stroke. Concepts and controversies. Stroke 2001;32:803-808.
62. Yamaguchi T, for Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. A multicenter, prospective, randomised trial. Stroke 2000;31:817-821.
63. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE: Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160:1612-1617.
64. Hylek EM, Singer DE: Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
65. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE: Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-662.
66. Palareti G, Hirsh J, Legnani C, Manotti C, D'Angelo A, Pengo V, Moia M, Guazzaloca G, Musolesi S, Coccheri S: Oral anticoagulation treatment in the elderly. A nested, prospective, case-control study. Arch Intern Med 2000;160:470-478.
67. Gitter MJ, Jaegger TM, Petterson TM, Gersh BJ, Silverstein MD: Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota. Mayo Clin Proc 1995;70:725-733.
68. Copland M, Walker ID, Tait RC: Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med 2001;161:2125-2128.
69. Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH, for the National Consortium of Anticoagulation Clinics: The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-979.
70. Huber J, Stöllberger C, Finsterer J, Schneider B, Länger T: Quality of blood pressure control and risk of cerebral bleeding in patients with oral anticoagulation. Acta Med Austriaca 2003;30:6-9.
71. Dawson I, van Bockel JH, Ferrari MD, van der Meer FJM, Brand R, Terpstra JL: Ischemic and hemorrhagic stroke in patients on oral anticoagulants after reconstruction for chronic lower limb ischemia. Stroke 1993;24:1655-1663.
72. Bernabei R, Gambassi G, Lapane K, Sgadari A, Landi F, Gatsonis C, Lipsitz L, Mor V, on behalf of the SAGE (Systematic Assessment of Geriatric Drug Use via Epidemiology) Study Group: Characteristics of the SAGE database: A new resource for research on outcomes in long-term care. J Gerontol Med Sci 1999;54A: M25-M33.
73. Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, Meyboomde Jong B: The development of polypharmacy. A longitudinal study. Fam Pract 2000;17:261-267.
74. Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T, Maillard L, Mas JL, Mentre F, Pousset F, Lacomblez L, Pisica G, Solbes-Latourette S, Raynaud P, Chaumet-Riffaud P, for the FFAACS Investigators: Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS). Cerebrovasc Dis 2001;12:245-252.
75. McKenna CJ, Galvin J, McCann HA, Sugrue DD: Risks of long-term oral anticoagulation in a non-trial medical environment. Ir Med J 1996;84:144-145.
76. Barcellona D, Contu P, Sorano GG, Pengo V, Marongiu F: The management of oral anticoagulant therapy: The patient's point of view. Thromb Haemost 2000;83:49-53.
77. Beyth RJ, Quinn L, Landefeld CS: A multi-component intervention to prevent major bleeding complications in older patients receiving warfarin. A randomised controlled trial. Ann Intern Med 2000;133:687-695.
78. Hufschmidt A, Lücking CH (eds): Neurologie compact. Leitlinien für Klinik und Praxis. Stuttgart, Thieme
79. Man-Son-Hing M, Nichol G, Lau A, Laupacis A: Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999;159:677-685.
80. Estrada CA, Hryniewicz MM, Higgs VB, Collins C, Byrd JC: Anticoagulant patient information material is written at high readability levels. Stroke 2000;31:2966-2970.
81. Stöllberger C, Finsterer J, Länger T, Schneider B, Wehinger C, Hopmeier P, Slany J: Problems, interventions and complications in long-term oral anticoagulation therapy. J Thromb Thrombolysis 2002;14:65-72.
82. Ansell JE, Patel N, Ostrovsky D, Nozzolillo E, Peterson AM, Fish L: Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995;155:2185-2189.
83. Kearon C, Hirsh J: Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-1511.
84. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M: Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-296.
85. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG: Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:381-392.
86. Parfitt K (ed): Martindale. The Complete Drug Reference, Ed 32. London, Pharmaceutical Press, 1999.